Patient Care Costs in Cancer Clinical Trials
Rep. Pryce is also cochair of the House Cancer Working Group. In March, she introduced the Access to Cancer Clinical Trials Act (H.R. 967), which would require health insurers to pay for the routine costs incurred by patients in
Rep. Pryce is also cochair of the House Cancer Working Group. InMarch, she introduced the Access to Cancer Clinical Trials Act(H.R. 967), which would require health insurers to pay for the routine costsincurred by patients in cancer clinical trials. This would be a further step infederal policy beyond the Clinton administration’s national coverage decisionthat went into effect in September 2000. The Pryce bill calls for coverage ofall participants in cancer clinical trials, regardless of age, including thoseconducted by nonfederal research entitiesa category of trials not included inthe Clinton policy.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
